Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Stock Chart & Stats
$81.99
-$0.75(-2.14%)
At close: 4:00 PM EST
$81.99
-$0.75(-2.14%)
Day’s Range― - ―
52-Week Range$23.95 - $82.95
Previous CloseN/A
Volume126.35K
Average Volume (3M)2.73M
Market Cap
$13.28B
Enterprise Value$10.26B
Total Cash (Recent Filing)$2.24B
Total Debt (Recent Filing)$1.49B
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Feb 25, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding161,974,400
10 Day Avg. Volume2,403,569
30 Day Avg. Volume2,734,297
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)8.88
Price to Sales (P/S)7.41
P/FCF Ratio-9.57
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue10.61
Enterprise Value/Gross Profit10.74
Enterprise Value/Ebitda-70.91
Forecast
1Y Price Target
$84.31Price Target Upside2.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-2.33
Revenue Forecast (FY)$896.03M
Bulls Say, Bears Say
Bulls Say
Market PositionIonis will potentially have an 18-month first-mover advantage, which should enable the company to gain a significant foothold in the market.
Pricing StrategyIonis plans to price olezarsen in sHTG at a significant discount compared to Arrowhead's pricing, which positions it competitively in the market.
Regulatory MilestonesGranting of FDA breakthrough therapy designation (BTD) is an incremental positive for Ionis that could expedite the launch date of olezarsen in severe hypertriglyceridemia (sHTG).
Bears Say
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $82.95 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $13.28B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Feb 25, 2026 which is in 85 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Oct 29, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.418.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.33.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 161,974,400 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -2.297%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.31 (2.83% Upside)
$84.31 (2.83% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.44%
12-Months-Change
Fundamentals
Return on Equity
-39.99%
Trailing 12-Months
Asset Growth
-1.56%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Ionis Pharmaceuticals demonstrated strong revenue growth and successful product launches, with significant advancements in their clinical pipeline. Despite these achievements, the company faces challenges with operating losses and patient identification for Tringolza. Overall, the positive developments outweigh the challenges.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$84.31
▲(2.83% Upside)
Technical Analysis
Alkermes
―
Cytokinetics
―
Sarepta Therapeutics
―
Axsome Therapeutics
―
Krystal Biotech
―
Ownership Overview
Currently, No data available
---